Literature DB >> 28144821

Nebulized Liposomal Amphotericin B for Treatment of Pulmonary Infection Caused by Hormographiella aspergillata: Case Report and Literature Review.

Cendrine Godet1,2, Estelle Cateau3,4, Blandine Rammaert5,3,6, Marine Grosset5, Gwenaël Le Moal5, Guillaume Béraud5,7,8, Jean Philippe Martellosio5, Xavier Iriart9,10, Jacques Cadranel11,12, France Roblot5,3,4.   

Abstract

Invasive fungal infection is a serious complication following allogeneic hematopoietic stem cell transplantation. Pulmonary infection due to Hormographiella aspergillata is an uncommon condition associated with a high mortality rate. The susceptibility of H. aspergillata to available antifungal agents is not well established. We report for the first time a case of H. aspergillata lung infection that responded poorly to conventional treatment with liposomal amphotericin B (LAmB; 3 mg kg-1 of body weight per day) with renal damage at higher posology (5 mg kg-1 of body weight per day), but improved rapidly after addition of nebulized LAmB to intravenous LAmB (3 mg kg-1 of body weight per day). Successful treatment of our patient using nebulized LAmB would be worth evaluating in cases refractory to standard treatment or when the reference treatment may not be extended due to interaction or side effects.

Entities:  

Keywords:  Hormographiella aspergillata; Lung; Nebulized liposomal amphotericin B; Treatment outcome

Mesh:

Substances:

Year:  2017        PMID: 28144821     DOI: 10.1007/s11046-017-0117-9

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  25 in total

1.  Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis.

Authors:  A Safdar; S O'Brien; I F Kouri
Journal:  Bone Marrow Transplant       Date:  2004-09       Impact factor: 5.483

2.  High negative predictive value diagnostic strategies for the reevaluation of early antifungal treatment: A multicenter prospective trial in patients at risk for invasive fungal infections.

Authors:  Lilia Hasseine; Sophie Cassaing; Florence Robert-Gangneux; Judith Fillaux; Pierre Marty; Jean-Pierre Gangneux
Journal:  J Infect       Date:  2015-04-18       Impact factor: 6.072

3.  Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey.

Authors:  A Cornillet; C Camus; S Nimubona; V Gandemer; P Tattevin; C Belleguic; S Chevrier; C Meunier; C Lebert; M Aupée; S Caulet-Maugendre; M Faucheux; B Lelong; E Leray; C Guiguen; J-P Gangneux
Journal:  Clin Infect Dis       Date:  2006-07-27       Impact factor: 9.079

Review 4.  Nebulised liposomal amphotericin B for Aspergillus lung diseases: case series and literature review.

Authors:  Cendrine Godet; Véronique Goudet; François Laurent; Gwenaël Le Moal; Valérie Gounant; Jean-Pierre Frat; Estelle Cateau; France Roblot; Jacques Cadranel
Journal:  Mycoses       Date:  2015-03       Impact factor: 4.377

5.  Breakthrough invasive mould infections in patients treated with caspofungin.

Authors:  Katy-Anna Phai Pang; Cendrine Godet; Arnaud Fekkar; Julie Scholler; Yasmine Nivoix; Valérie Letscher-Bru; Laurent Massias; Catherine Kauffmann-Lacroix; Antoine Elsendoorn; Madalina Uzunov; Annick Datry; Raoul Herbrecht
Journal:  J Infect       Date:  2011-12-29       Impact factor: 6.072

6.  Breakthrough Hormographiella aspergillata infections arising in neutropenic patients treated empirically with caspofungin.

Authors:  Felipe Suarez; Gaelle Olivier; Dea Garcia-Hermoso; Edouard Randriamalala; David Ghez; Julie Bruneau; Catherine Kauffmann-Lacroix; Marie-Elisabeth Bougnoux; Olivier Lortholary
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

Review 7.  Voriconazole : a review of its use in the management of invasive fungal infections.

Authors:  Lesley J Scott; Dene Simpson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant.

Authors:  Victor Monforte; Almudena López-Sánchez; Felipe Zurbano; Piedad Ussetti; Amparo Solé; Cristina Casals; José Cifrian; Alicia de Pablos; Carles Bravo; Antonio Román
Journal:  J Heart Lung Transplant       Date:  2013-01-16       Impact factor: 10.247

9.  Rhizomucor variabilis var. regularior and Hormographiella aspergillata infections in a leukemic bone marrow transplant recipient with refractory neutropenia.

Authors:  Mayssa M Abuali; Roberto Posada; Gustavo Del Toro; Elizabeth Roman; Rama Ramani; Sudha Chaturvedi; Vishnu Chaturvedi; Vincent J LaBombardi
Journal:  J Clin Microbiol       Date:  2009-10-21       Impact factor: 5.948

Review 10.  Recognizing filamentous basidiomycetes as agents of human disease: A review.

Authors:  Anuradha Chowdhary; Shallu Kathuria; Kshitij Agarwal; Jacques F Meis
Journal:  Med Mycol       Date:  2014-09-08       Impact factor: 4.076

View more
  5 in total

1.  The Curious Case of "Case Report" of Infections Caused by Human and Animal Fungal Pathogens: An Educational Tool, an Online Archive, or a Format in Need of Retooling.

Authors:  Jean-Philippe Bouchara; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2018-12       Impact factor: 2.574

Review 2.  Nebulised antibiotherapy: conventional versus nanotechnology-based approaches, is targeting at a nano scale a difficult subject?

Authors:  Esther de Pablo; Raquel Fernández-García; María Paloma Ballesteros; Juan José Torrado; Dolores R Serrano
Journal:  Ann Transl Med       Date:  2017-11

3.  Invasive Hormographiella aspergillata Infection Identified Using DNA Sequencing.

Authors:  Eunbin Chong; Hui-Jin Yu; Tae Yeul Kim; Keon Hee Yoo; Yae-Jean Kim; Hee Jae Huh; Nam Yong Lee
Journal:  Ann Lab Med       Date:  2022-05-01       Impact factor: 3.464

Review 4.  Inhaled Liposomal Antimicrobial Delivery in Lung Infections.

Authors:  Matteo Bassetti; Antonio Vena; Alessandro Russo; Maddalena Peghin
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

Review 5.  Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections.

Authors:  Kévin Brunet; Jean-Philippe Martellosio; Frédéric Tewes; Sandrine Marchand; Blandine Rammaert
Journal:  Pharmaceutics       Date:  2022-03-14       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.